Nabu 500 tablet: Each coated tablet contains Nabumetone BP 500 mg.
Nabu 750 tablet: Each coated tablet contains Nabumetone BP 750 mg.
Nabu is a preparation of Nabumetone which is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic properties in pharmacologic studies. As with other non-steroidal anti-inflammatory agents, its mode of action is not known; however, the ability to inhibit prostaglandin synthesis may be involved in the anti-inflammatory effect. The parent compound is a prodrug, which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid (6MNA), that is a potent inhibitor of prostaglandin synthesis.
Route of administration:
Nabu should be taken in oral route.The recommended starting dose of Nabu® is 1,000 mg taken as a single dose with or without food. Some patients may obtain more symptomatic relief from 1,500 mg to 2,000 mg per day. Nabu® can be given in either a single or twice daily dose. Dosages greater than 2,000 mg per day have not been studied. The lowest effective dose should be used for chronic treatment. Patients with renal impairment: Caution should be used in prescribing nabumetone to patients with moderate or severe renal insufficiency. The maximum starting doses of nabumetone in patients with moderate or severe renal insufficiency should not exceed 750 mg or 500 mg, respectively once daily. Following careful monitoring of renal function in patients with moderate or severe renal insufficiency, daily doses may be increased to a maximum of 1,500 mg and 1,000 mg respectively.
Warfarin and antiplatelets increase gastrointestinal bleeding risk; increases lithium and methotrexate plasma concentrations; attenuates antihypertensive effect of ACE inhibitors.
Nabumetone is contraindicated in patients with known history of hypersensitivity to nabumetone or any other components of this product. It is also contraindicated in NSAIDs induced asthma, urticaria or other allergic type reactions.
Common: Pruritus, skin burning/pain, diarrhea, dyspepsia, abdominal pain, constipation, flatulence, nausea, dry mouth, vomiting, dizziness, headache, fatigue, sweating, insomnia, somnolence, rash, tinnitus, edema. Less Common: Gastritis, stomatitis, contact dermatitis.
Overdose
Patients should be managed by symptomatic and supportive care following a NSAIDs overdose. There are no specific antidotes. Emesis and/or activated charcoal and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large overdose. Forced diuresis, alkalinization of urine, hemodialysis or hemoperfusion may not be useful due to high protein binding.
Category C (1st/2nd trimesters), Category D (3rd trimester). Avoid in 3rd trimester due to risk of premature closure of ductus arteriosus. Lactation: Prostaglandin inhibitors may affect neonates; not recommended in nursing mothers.
Store below 25°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.